Jefferies analyst Suji Jeong initiated coverage of Bellus Health with a Buy rating and $20 price target. The company is developing BLU-5937 for chronic cough, which offers a "large untapped market," Jeong tells investors in a research note. The analyst believes BLU-5937's "validated target and high selectivity pose" lower the clinical risks and position the drug as a potentially competitive drug for chronic cough. Although BLU-5937's timeline is behind its competitors, if the Phase 2 data in mid-2020 show similar efficacy as competitors but with low taste disturbance, the stock can more than double from current levels, contends Jeong. The analyst sees a "favorable" risk/reward for Bellus Health shares.